On September 1, 2026, the FDA publicly posted a warning letter — dated August 18 — to Shoolin Pharma Chem LLP, an Indian active-pharmaceutical-ingredient maker whose sildenafil citrate and tadalafil were, in the agency's own words, "imported into the United States and utilized by compounding pharmacies to produce medications for US citizens." Those are the active ingredients in generic Viagra and Cialis. Medical Daily brought the letter to wider attention on September 9.

Why It Matters

The telehealth ED boom was built on a price gap, and a meaningful share of that gap is supply-chain arbitrage: compounded preparations sourced from API makers that sit outside the approved-generic quality regime. This letter is the clearest public illustration yet of what that trade-off can look like at the factory floor. When a compounding pharmacy buys the active ingredient, the supplier effectively *becomes* the quality-control function — and here the supplier could not produce the test data behind its own certificates of analysis. The clinical stakes are not abstract. Sildenafil and tadalafil interact dangerously with nitrates, and the patients most likely to be on nitrates — men with diabetes, hypertension, high cholesterol or heart disease — overlap heavily with the men most likely to be prescribed these drugs. Uncertain potency, shared-equipment contamination and an unverifiable stability program are exactly the failure modes that make dose predictability matter. For the sector, this lands on top of an already-tightening compounding environment and the FDA's broader scrutiny of compounded GLP-1s. Platforms that lean on compounded formulations should expect harder questions — from regulators, from insurers, and increasingly from customers — about who supplies their API and what documentation backs it. The single most useful consumer question in the whole men's-health telehealth category is now also the simplest: is this FDA-approved, or compounded?

The inspection findings are grim in a very specific, documentable way. FDA investigators spent five days at the firm's Indrad plant in Gujarat's Mehsana district, April 13–17, 2026, and reported "layered unidentified residues," corroded equipment surfaces near open processing lines and API packaging, residues on production-area walls and floors, leaking transfer lines, and product transfer lines stored in ways that risked contamination. An employee was observed in open-toed sandals directly in front of open equipment during production. The agency declared the products adulterated under section 501(a)(2)(A) of the Federal Food, Drug, and Cosmetic Act — the insanitary-conditions provision — and separately adulterated under 501(a)(2)(B) for failing current good manufacturing practice for APIs.

The laboratory findings compound the problem. The firm used non-dedicated equipment to make ED ingredients alongside anticonvulsant and other compounds, a cross-contamination risk the FDA says it never evaluated. Per the letter and Medical Daily's read of it, the company could not produce underlying data supporting the certificates of analysis it issued with shipments; outside-lab results were reprinted on company letterhead without identifying who performed them; stability chambers used to justify labeled expiry dates were found powered off or out of temperature and humidity specification; and tadalafil samples scheduled for future testing could not be located. The FDA directed the firm to remediate its data-integrity practices.

The enforcement sequence matters for anyone tracking supply. The FDA held a teleconference with the firm on July 27 recommending a recall; the company began a voluntary recall on August 4 covering all of its APIs in US distribution, including sildenafil citrate and tadalafil labeled "For Prescription Compounding Only" and distributed nationwide. On August 11 the agency placed all of the firm's products on import alert, allowing shipments to be refused at the border. The FDA has not linked any injury or adverse event to these ingredients.

Brand-name Viagra and Cialis are not affected, and neither are FDA-approved generics from other manufacturers. The exposure sits entirely on the compounded side — preparations made by a licensed pharmacist or physician, which are not FDA-approved and which the agency does not review for safety, effectiveness or quality before they reach patients. Compounded sildenafil and tadalafil have become a routine offering on telehealth men's-health platforms, typically priced below branded prescriptions.

Sources

Update — 2026-09-11

{Initial entry — story first created.}